Accepted Manuscript

Design, synthesis and biological evaluation of quinazoline–phosphoramidate mustard conjugates as anticancer drugs

Songwen Lin, Yingbo Li, Yufen Zheng, Laichun Luo, Qi Sun, Zemei Ge, Tieming Cheng, Runtao Li

PII: S0223-5234(16)31061-3

DOI: 10.1016/j.ejmech.2016.12.055

Reference: EJMECH 9146

To appear in: *European Journal of Medicinal Chemistry*

Received Date: 8 October 2016

Revised Date: 26 December 2016

Accepted Date: 26 December 2016

Please cite this article as: S. Lin, Y. Li, Y. Zheng, L. Luo, Q. Sun, Z. Ge, T. Cheng, R. Li, Design, synthesis and biological evaluation of quinazoline–phosphoramidate mustard conjugates as anticancer drugs, *European Journal of Medicinal Chemistry* (2017), doi: 10.1016/j.ejmech.2016.12.055.

Design, synthesis and biological evaluation of quinazoline–phosphoramidate mustard conjugates as anticancer drugs

Songwen Lin[†], Yingbo Li[†], Yufen Zheng, Laichun Luo, Qi Sun[*], Zemei Ge, Tieming Cheng, Runtao Li*

State Key Lab of Natural and Mimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, P. R. China, 100191

Corresponding Authors

*Qi Sun: e-mail sunqi@bjmu.edu.cn; fax 86-10-82801571; tel 86-10-82801504.

* Runtao Li: e-mail lirt@ bjmu.edu.cn; fax 86-10-82805954; tel 86-10-82805954.

Author Contributions

† S. Lin and Y. Li contributed equally to this work.

Research highlight: 1) Phosphoramide mustard functionality incorporated into the quinazoline scaffold as EGFR/HER2 inhibitors were proposed. 2) The mechanism studies were supported on DNA damage. 3) Compound **10d** is a potential candidate for treatment of lung cancer. 4) MTD study indicated that compound **10d** had no obvious acute toxicity.